|
Drug shRNA peptide
|
Dual anti-HIV gene Transfer construct, LVsh5/C46 (Cal)
|
CCR5 shRNA; C46 peptide Busulfan
|
Host co-receptor; viral Env; transplant conditioning
|
NCT01734850
|
Phase I/II recruiting
|
Calimmune/CalTech/UCLA
|
|
shRNA
|
Long term follow up of delayed adverse events in Cal-1 recipients
|
Blood test for general health, complete blood count and Cal-1 specific analyses
|
NCT02390297
|
Recruiting by invitation
|
Calimmune/CalTech/UCLA
|
|
Endoribonuclease
|
Redirected MazF-CD4 autologous T-cells
|
CCR5 MazF
|
Host co-receptor
|
NCT01787994
|
Phase I ongoing
|
University of Pennsylvania
|
|
Ribozyme
|
Autologous CD34+ HSCs transduced with anti-HIV-1 ribozyme (OZ1)
|
Tat-vpr anti-HIV ribozyme
|
tat-vpr mRNA
|
NCT00074997
|
Phase II completed
|
Janssen-Cilag Pty Ltd, UCLA
|
|
Ribozyme
|
Long term follow up of OZ1 Gene therapy
|
Blood test for quantitative marking of the gene transfer product in PBMCs overtime
|
NCT01177059
|
Phase II Recruiting by invitation
|
Janssen-Cilag Pty Ltd, UCLA
|
|
Antisense
|
Tolerability and therapeutic effects of repeated doses of autologous T cells with VRX496
|
VRX496 antisense RNA
|
Env mRNA
|
NCT00295477
|
Phase I/II Ongoing/ not recruiting
|
University of Pennslyvernia/NIAID
|
|
Antisense
|
Safety and efficacy of T-cell genetic immunotherapy
|
VRX496 antisense RNA
|
Env mRNA
|
NCT00131560
|
Phase II Ongoing
|
VIRxSYS Corporation
|
|
Ribozyme
|
L-TR/Tat-neo in HIV+ Patients with Non-Hodgkin’s Lymphoma
|
Tat ribozyme
|
Tat-rev mRNA
|
NCT00002221
|
Phase II completed
|
Ribozyome/City of Hope
|
|
Inhibitory peptides
|
M87o autologous HSCs for HIV+ patients with malignant disease
|
C46 peptide
|
Viral Env
|
NCT00858793
|
Phase I/II suspended
|
University Medical Center Hamburg-Eppendorf
|
|
Ribozyme, inhibitory peptide
|
C46/CCR5/P140K modified autologous HSCs in patients with lymphoma
|
C46 peptide, CCR5 ribozyme, MGMTP140 K mutant
|
Viral Env, CCR5 mRNA, Alkylating agent resistance
|
NCT02343666
|
Phase I, recruiting
|
Fred Hutchinson Cancer Research Center/NCI/NHLBI
|
|
shRNA,peptide
|
Autologous transplantation of HSCs with LVsh5/C46 (Cal-1) for treatment of HIV-related lymphoma
|
CCR5 shRNA, C46 peptide
|
Host co-receptor, viral Env
|
NCT02378922
|
Phase I recruiting
|
Fred Hutchinson Cancer Research Center/NCI
|
|
shRNA, ribozyme,RNA decoy, drugs
|
rHIV7-shI-TAR-CCR5RZ-transduced HSC in patient with AIDS-related Non-Hodgkin Lymphoma
|
tat/rev shRNA, TAR decoy, CCR5 ribozyme, Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide
|
Viral mRNA, Viral tat proteinm, CCR5 mRNA, Transplant conditioning
|
NCT02337985
|
Pilot recruiting
|
City of Hope Medical Center/NCI
|
|
shRNA, ribozyme,RNA decoy, drugs
|
rHIV7-shI-TAR-CCR5RZ-transduced HSC in patient with AIDS-related Non-Hodgkin Lymphoma
|
tat/rev shRNA, TAR decoy, CCR5 ribozyme, Busulfan
|
Viral mRNA, Viral tat proteinm, CCR5 mRNA
|
NCT01961063
|
Pilot recruiting
|
City of Hope Medical Center/NCI
|
|
shRNA, ribozyme,RNA decoy, drugs
|
rHIV7-shI-TAR-CCR5RZ-transduced HSC in patient undergoing stem cell transplant for AIDS-related lymphoma
|
tat/rev shRNA, TAR decoy, CCR5 ribozyme, carmustine, cyclophosphamide, etoposide
|
viral mRNA, viral tat protein, CCR5 mRNA, transplant conditioning
|
NCT00569985
|
Pilot ongoing, not recruiting
|
City of Hope Medical Center/NCI
|
|
shRNA, RNA decoy
|
shRNA/TRIM5alpha/TAR decoy-transduced Autologous HSC in patient with HIV-Related Lymphoma
|
CCR5 shRNA, RNF88,TAR decoy
|
Host co-receptor, Gag p24, Viral tat protein
|
NCT02797470
|
Phase I/II
|
City of Hope Medical Center/NCI
|
|
RNA decoy
|
RNA decoy (ex vivo retroviral modified CD34+ HPC)
|
Rev reponse element decoy
|
Rev Protein
|
NCT00001535
|
Phase 0-pilot
|
Children’s Hospital
|
|
Redirected high affinity gag-specific autologous T cells
|
WT-gag-TCR or alpha/6-gag-TCR
|
CD8 TCR
|
NCT00991224
|
Phase I completed
|
University of Pennslyvernia/Adaptimmune
|
|
ZFN
|
T-cells modified at CCR5 gene by ZFN SB-728mR
|
CCR5 ZFN
|
CCR5 DNA
|
NCT02388594
|
Phase 1 recruiting
|
University of Pennsylvania/NIAID
|
|
Repeated doses of SB-728mR-T after cyclophosphamide conditioning in HIV+ on HAART
|
CCR5 ZFN (SB-728mR-T)
|
CCR5 DNA
|
NCT02225665
|
PHASE I/II ongoing
|
Sangamo biosciences
|
|
Autologous T cells modified at CCR5 gene by ZFN SB-728
|
CCR5 ZFN
|
CCR5 DNA
|
NCT00842634
|
Phase 1 completed
|
Sangamo biosciences/ Uni. Of Pennsylvania
|
|
Autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases (SB-728-T) in HIV-infected patients
|
CCR5 ZFN
|
CCR5 DNA
|
NCT01044654
|
Phase I completed
|
Sangamo Therapeutics
|
|
Safety of ZFN CCR5-modified HPS/progenitor cells in HIV+
|
SB-728mR-HSPC infusion after busulfan conditioning
|
CCR5 DNA
|
NCT02500849
|
Phase 1
|
City of Hope Medical Center|Sangamo Therapeutics
|
|
Autologous T-cells genetically modified at the CCR5 Gene by zinc finger nucleases in HIV-infected subjects
|
CCR5 ZFN (SB-728-T)
|
CCR5 DNA
|
NCT01252641
|
Phase I/II completed
|
Sangamo Therapeutics
|
